<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380587</url>
  </required_header>
  <id_info>
    <org_study_id>XCL1 in ALL</org_study_id>
    <nct_id>NCT01380587</nct_id>
  </id_info>
  <brief_title>Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia</brief_title>
  <acronym>XCL1</acronym>
  <official_title>Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the utility of XCL1 in the prognosis of acute
      lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year approximately 256,000 children and adults around the world develop a form of
      leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship
      between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia.
      XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one
      cysteine in the N-terminal residue. It has been found with significant expression of receptor
      mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these
      reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic
      leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with poor prognosis and high levels of XCL1</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with high levels of XCL1, expression of its receptor and other cytokines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with poor prognosis and high levels of cytokines</measure>
    <time_frame>3 months</time_frame>
    <description>Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <description>We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, blasts
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will invite patients with newly diagnosed acute lymphoblastic leukemia , who had not
        received anticancer therapy and regardless the subtype and immunophenotype of the disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with newly diagnosed acute lymphoblastic leukemia .

        Exclusion Criteria:

          -  Patients with prior treatment with chemotherapeutic agents.

          -  Patients treated with immunosuppressants.

          -  Patients under 12 months old.

          -  Patients with a diagnosis or history of autoimmune diseases.

          -  Patients with a diagnosis or history of immunosuppressive diseases.

          -  Patients who do not agree to sign a Letter of Informed Consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar H Gutierrez Aguirre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez UANL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E. Gonzalez UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Huang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem Biophys Res Commun. 2001 Feb 23;281(2):378-82.</citation>
    <PMID>11181058</PMID>
  </reference>
  <reference>
    <citation>Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol. 1994 Aug;1(4):229-46. Review.</citation>
    <PMID>7584498</PMID>
  </reference>
  <reference>
    <citation>Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene &quot;intercrine&quot; cytokine family. Annu Rev Immunol. 1991;9:617-48. Review.</citation>
    <PMID>1910690</PMID>
  </reference>
  <reference>
    <citation>Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 Feb 13;385(6617):640-4.</citation>
    <PMID>9024663</PMID>
  </reference>
  <reference>
    <citation>Rollins BJ. Chemokines. Blood. 1997 Aug 1;90(3):909-28. Review.</citation>
    <PMID>9242519</PMID>
  </reference>
  <reference>
    <citation>Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol. 2003 Nov 1;171(9):4528-38.</citation>
    <PMID>14568926</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>XCL1</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

